Crinetics Pharmaceuticals Awarded $2.8 Million SBIR Grant to Support Development of Acromegaly Drug Candidate CRN00808
13 juil. 2017 13h00 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, July 13, 2017 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, announced today that...
Lumenari Selected for DoD SBIR Awards
14 juin 2017 08h00 HE
|
Startup Evo, LLC
Lexington, June 14, 2017 (GLOBE NEWSWIRE) -- Lumenari was recently selected for two Phase I awards in the United States Department of Defense (DoD) Small Business Innovative Research (SBIR) Program...
Advanced Space Resource Utilization Technology Projects Supported by New NASA Awards to Deep Space Industries
12 mai 2015 14h19 HE
|
Deep Space Industries Inc.
SILICON VALLEY, Calif., May 12, 2015 (GLOBE NEWSWIRE) -- NASA has selected Deep Space Industries (DSI) for two contracts devoted to developing critical technologies for utilizing asteroid resources....
Xeris Pharmaceuticals Awarded Phase I-II NIH SBIR Fast Track Grant to Advance Stable, Non-Aqueous Glucagon for Treatment of Congenital Hyperinsulinism, an Orphan Disease
14 avr. 2015 14h00 HE
|
Xeris Pharmaceuticals, Inc.
Austin, Texas, April 14, 2015 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”), an Austin-based, emerging biopharmaceutical company developing patient-friendly injectable treatments for...
Xeris Pharmaceuticals Closed 2012 with $6M In Additional Funding
11 févr. 2013 09h42 HE
|
Xeris Pharmaceuticals, Inc.
Austin, TX, Feb. 11, 2013 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), an Austin-based, emerging
pharmaceutical company developing patient-friendly injectable
treatments for diabetes,...
Xeris Pharmaceuticals Awarded Phase I-II NIH SBIR Fast Track Grant to Advance Stable, Non-Aqueous Glucagon for Bi-Hormonal Artificial Pancreas
31 juil. 2012 10h41 HE
|
Xeris Pharmaceuticals, Inc.
Austin, TX, July 31, 2012 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), an Austin-based, emerging
biopharmaceutical company developing patient-friendly injectable
treatments for diabetes...
SPIE Applauds Congress for Support of SBIR Reauthorization
15 déc. 2011 16h34 HE
|
SPIE
BELLINGHAM, WA--(Marketwire - Dec 15, 2011) - SPIE leaders said they were pleased with the announcement earlier this week by House committee leaders that they had successfully negotiated a deal...
Stellar Biotechnologies Announces Significant Expansion of Keyhole Limpet Hatchery & Sera Production Capability
06 déc. 2011 09h18 HE
|
Stellar Biotechnologies, Inc.
PORT HUENEME, CA--(Marketwire - Dec 6, 2011) - Stellar Biotechnologies, Inc. ("Stellar") (TSX VENTURE: KLH) (PINKSHEETS: SBOTF) is pleased to announce the completion of a major expansion of its...
Recent News Stories Highlight Stellar Biotechnologies
22 nov. 2011 09h05 HE
|
Stellar Biotechnologies, Inc.
PORT HUENEME, CA--(Marketwire - Nov 22, 2011) - Stellar Biotechnologies, Inc. "Stellar" (TSX-V: KLH) (PINKSHEETS: SBOTF) is pleased to report two recent news stories on the company, by the National...
Stellar Biotechnologies Awarded $498,560 Phase IIB National Science Foundation (NSF) Grant
29 août 2011 16h05 HE
|
Stellar Biotechnologies, Inc.
PORT HUENEME, CA--(Marketwire - Aug 29, 2011) - Stellar Biotechnologies, Inc. "Stellar" (TSX-V: KLH) (PINKSHEETS: SBOTF) is pleased to announce that the National Science Foundation (NSF) has...